FindTrial
Sign In

Study on serum level of IL-27 and its effect on myocardial fibrosis in patients with atrial fibrillation

Study on serum level of IL-27 and its effect on myocardial fibrosis in patients with atrial fibrillation

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300077669
Enrollment
Unknown
Registered
2023-11-15
Start date
2023-11-15
Completion date
Unknown
Last updated
2023-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atrial fibrillation

Interventions

Case series:NA

Sponsors

The Second Affiliated Hospital of Harbin Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: Nonvalvular paroxysmal or persistent atrial fibrillation; Age >18 years old; Meet radiofrequency ablation (RFCA) criteria and undergo surgery; Sign informed consent

Exclusion criteria

Exclusion criteria: Atrial fibrillation due to hyperthyroidism; Myocardial infarction within the last 3 months; A transient ischemic attack (TIA) or stroke within the last 30 days; Acute infection; Chronic kidney disease requiring dialysis; Severe liver insufficiency; History of malignant tumors within the past 5 years; History of autoimmune disease or immunodeficiency; Are pregnant or planning to become pregnant.

Design outcomes

Primary

MeasureTime frame
Interleukin 27;Atrial fibrosis degree;—

Countries

China

Contacts

Public ContactCao Wei

The Second Affiliated Hospital of Harbin Medical University, Nangang District, Harbin City, Heilongjiang Province

caowei3442@126.com+86 189 4610 6120

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026